Edition:
United Kingdom

DBV Technologies SA (DBV.PA)

DBV.PA on Paris Stock Exchange

16.97EUR
22 May 2019
Change (% chg)

-- (--)
Prev Close
€16.97
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
325,619
52-wk High
€44.20
52-wk Low
€7.59

Latest Key Developments (Source: Significant Developments)

DBV Technologies Announces Departure Of Deputy CEO David Schilansky
Tuesday, 14 May 2019 

May 14 (Reuters) - DBV TECHNOLOGIES SA ::DBV TECHNOLOGIES ANNOUNCES DEPARTURE OF DEPUTY CEO DAVID SCHILANSKY.NEW CHIEF FINANCIAL OFFICER SEARCH IS UNDERWAY, DBV WILL NOT FILL DEPUTY CEO ROLE FOLLOWING DAVID'S DEPARTURE.DAVID WILL REMAIN AT COMPANY THROUGH AUGUST 2019.DEPUTY CHIEF EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER, DAVID SCHILANSKY, HAS DECIDED TO LEAVE COMPANY TO PURSUE OTHER PROFESSIONAL OPPORTUNITIES.  Full Article

DBV Technologies Cash As Of March 31 Was 76.0 Million Euros
Tuesday, 30 Apr 2019 

April 30 (Reuters) - DBV TECHNOLOGIES SA ::CASH AND CASH EQUIVALENTS AS OF MARCH 31, 2019, WERE EUR 76.0 MILLION, COMPARED TO EUR 122.8 MILLION AS OF DECEMBER 31, 2018..  Full Article

DBV Technologies Appoints Michel De Rosen As Non-Executive Chairman
Tuesday, 5 Mar 2019 

March 5 (Reuters) - DBV TECHNOLOGIES SA ::REG-DBV TECHNOLOGIES ANNOUNCES APPOINTMENT OF MICHEL DE ROSEN AS NON-EXECUTIVE CHAIRMAN OF THE BOARD OF DIRECTORS.MR. DE ROSEN SUCCEEDS DBV TECHNOLOGIES’ CO-FOUNDER, DR. PIERRE-HENRI BENHAMOU, WHO RETIRED FROM HIS POSITION AS DBV’S NON-EXECUTIVE CHAIRMAN AND BOARD MEMBER.  Full Article

Cohen Milstein Announces Investigation Of DBV Technologies
Monday, 4 Mar 2019 

March 4 (Reuters) - DBV TECHNOLOGIES SA ::COHEN MILSTEIN ANNOUNCES INVESTIGATION OF DBV TECHNOLOGIES S.A..COHEN MILSTEIN SAYS INVESTIGATION TO DETERMINE IF DBV AND CERTAIN OF ITS OFFICERS AND DIRECTORS MADE FALSE AND MISLEADING STATEMENTS AND/OR OMISSIONS IN VIOLATION OF SECTIONS 10(B) AND 20(A) OF SECURITIES EXCHANGE ACT OF 1934.COHEN MILSTEIN SAYS CLASS ACTION LAWSUIT WAS FILED BY ANOTHER LAW FIRM ON BEHALF OF PURCHASERS OF COMMON STOCK OF DBV BETWEEN FEB 14, 2018 AND DEC 9, 2018, INCLUSIVE.COHEN MILSTEIN SAYS COMPLAINT ALLEGES DBV MISREPRESENTED AND/OR FAILED TO DISCLOSE THAT: BIOLOGICS LICENSE APPLICATION FOR VIASKIN PEANUT FAILED TO PROVIDE FDA WITH SUFFICIENT DATA ON MANUFACTURING PROCEDURES AND QUALITY CONTROLS.COHEN MILSTEIN SAYS COMPLAINT ALLEGES DBV MISREPRESENTED AND/OR FAILED TO DISCLOSE THAT: DBV WOULD HAVE TO WITHDRAW THE BIOLOGICS LICENSE APPLICATION FOR VIASKIN PEANUT.COHEN MILSTEIN SAYS COMPLAINT ALLEGES DBV MISREPRESENTED AND/OR FAILED TO DISCLOSE THAT: DBV'S STATEMENTS ABOUT ITS BUSINESS, OPERATIONS AND PROSPECTS WERE MATERIALLY FALSE AND/OR MISLEADING AND/OR LACKED A REASONABLE BASIS AT ALL RELEVANT TIMES.  Full Article

DBV Technologies Says Dr. Hugh Sampson To Assume Role Of Interim Chief Medical Officer
Thursday, 3 Jan 2019 

Jan 3 (Reuters) - DBV TECHNOLOGIES SA ::SAYS DR. HUGH SAMPSON TO ASSUME ROLE OF INTERIM CHIEF MEDICAL OFFICER.APPOINTMENT EFFECTIVE FROM JANUARY 3.  Full Article

DBV Technologies Appoints Daniel Tassé As Chief Executive Officer
Friday, 16 Nov 2018 

Nov 16 (Reuters) - DBV TECHNOLOGIES SA ::REG-DBV TECHNOLOGIES APPOINTS DANIEL TASSÉ AS CHIEF EXECUTIVE OFFICER.APPOINTED DANIEL TASSÉ AS ITS CHIEF EXECUTIVE OFFICER (CEO) EFFECTIVE NOVEMBER 29, 2018.CO-FOUNDER DR. PIERRE-HENRI BENHAMOU TO RETIRE AS CEO AND SERVE AS NON-EXECUTIVE CHAIRMAN OF THE BOARD.  Full Article

Dbv Technologies To Present Data Further Supporting Use Of Epicutaneous Immunotherapy For Treatment Of Peanut Allergy At 2018 Acaai Meeting
Friday, 9 Nov 2018 

Nov 9 (Reuters) - DBV Technologies SA ::DBV TECHNOLOGIES TO PRESENT DATA FURTHER SUPPORTING USE OF EPICUTANEOUS IMMUNOTHERAPY FOR TREATMENT OF PEANUT ALLERGY AT 2018 ACAAI MEETING."INCREASED REACTIVITY THRESHOLD IN PEANUT-ALLERGIC SUBJECTS TREATED WITH 12 MONTHS OF EPICUTANEOUS VIASKIN PEANUT" WILL BE PRESENTED BY DR. CARLA M. DAVIS."QUANTITATIVE RISK REDUCTION THROUGH EPICUTANEOUS IMMUNOTHERAPY (EPIT): RESULTS FROM PEPITES PHASE III TRIAL" WILL BE PRESENTED BY DR. BENJAMIN C. REMINGTON."SERUM BIOMARKERS OF IMMUNOMODULATION DURING PEANUT EPICUTANEOUS IMMUNOTHERAPY (EPIT) IN PEANUT-ALLERGIC SUBJECTS" WILL BE PRESENTED BY DR. MATTHEW GREENHAWT.  Full Article

DBV Technologies Submits Biologics License Application For Viaskin Peanut To FDA
Monday, 22 Oct 2018 

Oct 22 (Reuters) - DBV TECHNOLOGIES SA ::REG-DBV TECHNOLOGIES ANNOUNCES SUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR VIASKIN PEANUT TO THE U.S. FOOD AND DRUG ADMINISTRATION.  Full Article

DBV Technologies Reports H1 Net Loss Of 72.1 Million Euros
Friday, 7 Sep 2018 

Sept 7 (Reuters) - DBV TECHNOLOGIES SA ::REG-DBV TECHNOLOGIES : REPORTS FIRST HALF 2018 FINANCIAL RESULTS.CASH POSITION: CASH AND CASH EQUIVALENTS AS OF JUNE 30, 2018, WERE EUR 202.2 MILLION, COMPARED TO EUR 137.9 MILLION AS OF DECEMBER 31, 2017.NET LOSS: NET LOSS WAS EUR (72.1) MILLION FOR FIRST HALF 2018, COMPARED TO EUR (72.5) MILLION FOR FIRST HALF 2017.RESEARCH AND DEVELOPMENT EXPENSES DECREASED BY EUR 2.6 MILLION, OR 4.9%, TO EUR 49.9 MILLION IN FIRST HALF 2018,.OPERATING INCOME WAS EUR 7.3 MILLION FOR FIRST HALF 2018 COMPARED TO EUR 7.6 MILLION FOR PRIOR-YEAR PERIOD.  Full Article

DBV Technologies Reports Cash position of 234.5 Million Euros at end March
Friday, 27 Apr 2018 

April 27 (Reuters) - DBV TECHNOLOGIES SA ::REG-DBV TECHNOLOGIES REPORTS MARCH 31, 2018 CASH POSITION.CASH AND CASH EQUIVALENTS AS OF MARCH 31, 2018, WERE EUR 234.5 MILLION.  Full Article

BRIEF-DBV Technologies FY Net Loss Widens To 166.1 Million Euros

* REPORTED ON TUESDAY FY SALES AND MARKETING EXPENSES EUR 32.2 MLN VS EUR 15.8 MLN YR AGO